tetano
Editor, Senior Moderator
Can J Respir Ther
. 2023 Jan 20;59:52-65.
doi: 10.29390/cjrt-2022-005. eCollection 2023.
Effectiveness of high-flow nasal cannula therapy on clinical outcomes in adults with COVID-19: A systematic review
Daiana Gonçalves Arruda[SUP] 1 [/SUP], George Alvício Kieling[SUP] 2 [/SUP], Lucélia Luna Melo-Diaz[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction/background: Coronavirus disease 2019 (COVID-19) has high transmissibility and mortality rates. High-flow nasal cannula therapy (HFNC) might reduce the need for orotracheal intubation, easing the burden on the health system caused by COVID-19. The objective of the present study was to examine the effectiveness of HFNC in adult patients hospitalized with COVID-19. Specifically, the present study explores the effects of HFNC on rates of mortality, intubation and intensive care units (ICU) length of stay. The present study also seeks to define predictors of success and failure of HFNC.
Methods: A systematic literature search was conducted in the PubMed, EMBASE and SCOPUS databases, and the study was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Study quality was assessed using the National Heart, Lung, and Blood Institute's Study Quality Assessment Tools.
Results: The search identified 1,476 unique titles; 95 articles received full-text reviews and 40 studies were included in this review. HFNC was associated with a reduction in the rate of orotracheal intubation, notably when compared to conventional oxygen therapy. Studies reported inconsistency in whether HFNC reduced ICU length of stay or mortality rates. Among the predictors of HFNC failure/success, a ratio of oxygen saturation index of approximately 5 or more was associated with HFNC success.
Conclusion: In adult patients hospitalized with COVID-19, HFNC may prove effective in reducing the rate of orotracheal intubation. The ratio of the oxygen saturation index was the parameter most examined as a predictor of HFNC success. Low-level research designs, inherent study weaknesses and inconsistent findings made it impossible to conclude whether HFNC reduces ICU length of stay or mortality. Future studies should employ higher level research designs.
Keywords: COVID-19; intensive care units; intratracheal; intubation; nasal cannula; oxygen inhalation therapy; respiratory insufficiency.
. 2023 Jan 20;59:52-65.
doi: 10.29390/cjrt-2022-005. eCollection 2023.
Effectiveness of high-flow nasal cannula therapy on clinical outcomes in adults with COVID-19: A systematic review
Daiana Gonçalves Arruda[SUP] 1 [/SUP], George Alvício Kieling[SUP] 2 [/SUP], Lucélia Luna Melo-Diaz[SUP] 2 [/SUP]
Affiliations
- PMID: 36741308
- PMCID: PMC9854387
- DOI: 10.29390/cjrt-2022-005
Abstract
Introduction/background: Coronavirus disease 2019 (COVID-19) has high transmissibility and mortality rates. High-flow nasal cannula therapy (HFNC) might reduce the need for orotracheal intubation, easing the burden on the health system caused by COVID-19. The objective of the present study was to examine the effectiveness of HFNC in adult patients hospitalized with COVID-19. Specifically, the present study explores the effects of HFNC on rates of mortality, intubation and intensive care units (ICU) length of stay. The present study also seeks to define predictors of success and failure of HFNC.
Methods: A systematic literature search was conducted in the PubMed, EMBASE and SCOPUS databases, and the study was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Study quality was assessed using the National Heart, Lung, and Blood Institute's Study Quality Assessment Tools.
Results: The search identified 1,476 unique titles; 95 articles received full-text reviews and 40 studies were included in this review. HFNC was associated with a reduction in the rate of orotracheal intubation, notably when compared to conventional oxygen therapy. Studies reported inconsistency in whether HFNC reduced ICU length of stay or mortality rates. Among the predictors of HFNC failure/success, a ratio of oxygen saturation index of approximately 5 or more was associated with HFNC success.
Conclusion: In adult patients hospitalized with COVID-19, HFNC may prove effective in reducing the rate of orotracheal intubation. The ratio of the oxygen saturation index was the parameter most examined as a predictor of HFNC success. Low-level research designs, inherent study weaknesses and inconsistent findings made it impossible to conclude whether HFNC reduces ICU length of stay or mortality. Future studies should employ higher level research designs.
Keywords: COVID-19; intensive care units; intratracheal; intubation; nasal cannula; oxygen inhalation therapy; respiratory insufficiency.